The text starts here.

News Release

FOR IMMEDIATE RELEASE
May 24, 2010
For Print (PDF 145KB)

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PIPELINE, PORTFOLIO AT ASCO ANNUAL MEETING

HIGHLIGHTS INCLUDE NEW PHASE III DATA ON INVESTIGATIONAL ANTICANCER AGENT ERIBULIN IN LOCALLY RECURRENT OR METASTATIC BREAST CANCER


Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that fifteen abstracts highlighting the latest results from studies with its pipeline and portfolio products on metastatic breast cancer, ovarian cancer, non-small cell lung cancer, metastatic brain cancer, T-cell lymphoma and other cancers have been accepted for presentation during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, United States from June 4 to June 8, 2010.

Among the studies to be presented is an oral presentation of new data from a global phase III study (EMBRACE: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) of the Company's investigational anticancer agent eribulin mesylate (generic name, “eribulin”). The EMBRACE Study is an open-label, randomized, parallel two-arm, multi-center study of eribulin versus treatment of physicians choice in patients with locally recurrent or metastatic breast cancer previously treated with at least two chemotherapy regimens including an anthracycline and a taxane.

Eisai has long positioned integrative oncology as a therapeutic area of focus and has continued to prioritize the allocation of resources to research and development in this area. The accepted studies collectively reflect the Company's oncology pipeline and product portfolio strategy as well as pre-clinical and clinical oncology research.

Eisai will continue its commitment to actively pursuing the global discovery, development and production of oncology therapies representative of its human health care (hhc) philosophy to increase benefits to patients and their families, thereby making further contributions to addressing the diversified needs of and increasing the benefits to patients and their families as well as healthcare providers.


The following fourteen abstracts on Eisai's pipeline and portfolio products are accepted for presentation at this year's ASCO meeting:

Product Abstract Details Location Details
Eribulin Mesylate
(E7389)
Abstract No: CRA1004
A phase III study (EMBRACE) of eribulin mesylate versus treatment of physicians choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane

Oral presentation

June 8, 2010
9:30 AM-12:30 AM
Location: E Hall D1
Eribulin Mesylate
(E7389)
Abstract No: 1081
Efficacy and safety of eribulin in Japanese patients with advanced breast cancer

Poster session

June 5, 2010
2:00 PM-6:00 PM
Location: S Hall A2
Eribulin Mesylate
(E7389)
Abstract No: 2589
Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors

Poster session

June 7, 2010
8:00 AM-12:00 PM
Location: S Hall A2
Eribulin Mesylate
(E7389)
Abstract No: 2582
Eribulin mesylate pharmacokinetics in patients with hepatic impairment

Poster session

June 7, 2010
8:00 AM-12:00 PM
Location: S Hall A2
Farletuzumab (MORAb-003)
Abstract No: 5001
Efficacy and safety of farletuzamab, a humanized monocolonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study

Oral presentation

June 7, 2010
9:45 AM-11:15 AM
Location: E Arie
Crown Theatre
Farletuzumab
(MORAb-003)
Abstract No:
TPS255
A randomized, double blind, placebo controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer

Poster session

June 7, 2010
8:00 AM E2:00 PM
Location: S Hall A2
E7820
Abstract No: 3537
Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC)

Poster Session

June 6, 2010
2:00 PM-6:00 PM
Location: S Hall A2
Ontak®
(denileukin diftitox)
Abstract No: 8045
Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial

Poster session discussion

June 4, 2010
5:00 PM-6:00 PM
Location: E354b
E7080
Abstract No: 2540
A Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors

Poster session

June 7, 2010
8:00 AM-12:00 PM
Location: S Hall A2
E6201
Abstract No: 2505
A Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors

Oral presentation

June 6, 2010
8:00 AM-9:30 AM
Location: E354a
Gliadel® Wafer
Abstract No: 2066
A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one-to- three brain metastases: Preliminary results

Poster session

June 6, 2010
8:00 AM-12:00 PM
Location: S Hall A2
Dacogen®
(decitabine)
Abstract No: 6600
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS)

Poster session

June 5, 2010
8:00 AM-12:00 PM
Location: S Hall A2
Dacogen®
(decitabine)
Abstract No: 6601
Hematologic outcomes of MDS treatment with hypomethylating agents in community practice

Poster session

June 5, 2010
8:00 AM-12:00 PM
Location: S Hall A2
Fragmin®
(dalteparin sodium)
Abstract No: 9115
A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer

Poster session

June 7, 2010
1:00 PM-5:00 PM
Location: S Hall A2
Aloxi®
(palonosetron hydrochloride)
Abstract No: 9127
Chemotherapy induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT3-RA anti-emetic regimens

Poster session

June 7, 2010
1:00 PM-5:00 PM
Location: S Hall A2

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120